OncoMatch/GIST (Gastrointestinal Stromal Tumor)/PDGFRA
GIST (Gastrointestinal Stromal Tumor)PDGFRA Clinical Trials
PDGFRA mutations occur in approximately 10% of GIST; the D842V variant (~5–8%) is uniquely imatinib-resistant and defines the primary indication for avapritinib, an FDA-approved selective KIT/PDGFRA inhibitor. Non-D842V PDGFRA mutations show variable imatinib sensitivity. Trials investigate avapritinib in the neoadjuvant setting for resectable PDGFRA D842V GIST, and novel switch-inhibitors for non-D842V PDGFRA-mutant disease.
Top recruiting PDGFRA GIST (Gastrointestinal Stromal Tumor) trials
Ranked by phase and US site count. See all 6 trials matched to your profile →
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
Deciphera Pharmaceuticals, LLC
Imatinib TDM in GIST
Reema A. Patel
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Asan Medical Center
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
Asan Medical Center
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
IDRx Inc. - A GSK Company
Browse other molecular targets with active GIST (Gastrointestinal Stromal Tumor) trials.